跳至主要内容
临床试验/NCT06089135
NCT06089135已完成不适用

Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial (Short-Cut)

Baim Institute for Clinical Research22 个研究点 分布在 1 个国家目标入组 413 人开始时间: 2023年12月31日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
413
试验地点
22
主要终点
Primary Endpoint

研究概览

简要总结

The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized controlled trial that is designed to compare the efficacy of cutting balloon angioplasty vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.

详细描述

The trial will be composed of two cohorts:

  • Patients treated with up-front rotational atherectomy
  • Patients in whom atherectomy is not planned

Randomization to either cutting balloon angioplasty or intravascular lithotripsy will occur as follows in the 2 cohorts:

  • After rotational atherectomy is safely completed In the rotational atherectomy arm
  • After safe and successful wire crossing in patients in whom atherectomy is not planned.

The trial is designed to demonstrate non-inferiority between cutting balloon angioplasty and intravascular lithotripsy in each cohort with regards to the primary endpoint of post-procedural stent area as measured by intravascular imaging at the site of maximal calcification.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1. Subject is > 21 years old
  • Subject with an indication for PCI for the treatment of a) stable coronary artery disease; b) unstable angina; or c) NSTEMI with evidence of down-trending biomarkers
  • Subject is willing and able to provide informed written consent Angiographic Inclusion Criteria
  • The target lesion is a de novo native coronary lesion
  • The target vessel is a native coronary artery with either:
  • A stenosis > 70%; or,
  • A stenosis > 50% and <70% with evidence of ischemia via either positive stress test, FFR value < 0.80 or RFR/iFR/DFR value < 0.89
  • The reference diameter of the target vessel is > 2.5mm and < 4.0 mm at the lesion site
  • The target lesion has evidence of significant calcium at the lesion site defined either as,
  • The presence of radiopacities involving both sides of the arterial wall > 5mm and involving the target lesion on angiography
  • the presence of > 270o arc of superficial calcium on intravascular imaging with a length > 5mm or the presence of 360o arc of superficial calcium

排除标准

  • Patient is pregnant
  • Patient is actively participating in another clinical trial
  • Known LVEF < 25%
  • Ongoing Non-STEMI with rising biomarkers
  • Cardiogenic shock or requirement for mechanical/pharmacologic hemodynamic support
  • Planned use in the randomized lesion of a bare metal stent or non-stent treatment only
  • Patient has a known allergy to contrast which cannot be adequately pre-treated
  • Patient has a history of bleeding or coagulopathy and is unable to receive blood transfusion if needed
  • Patient presents with STEMI
  • Patient is unable to tolerate dual anti-platelet therapy
  • Patient has suffered a recent cerebrovascular event (stroke/TIA) within last 30 days
  • Angiographic Exclusion Criteria
  • Presence of large thrombus in the target vessel
  • Inability to pass coronary guidewire across the lesion
  • The target vessel has excessive tortuosity (Defined as presence of 2+ bends > 90o or 3+ bends > 75o) or other anatomic considerations that precludes intravascular imaging
  • The target lesion is within a coronary artery bypass graft
  • The target lesion involves a bifurcation lesion in which either a 2-stent strategy is planned or both branches are planned for calcium modification
  • Coronary artery disease that requires surgical revascularization
  • Angiographic or imaging evidence of dissection in the target vessel prior to randomization
  • Investigator feels there is not equipoise regarding the treatment strategy

研究组 & 干预措施

Intravascular Lithotripsy

Active Comparator

干预措施: Intravascular Lithotripsy (Device)

Cutting Balloon

Active Comparator

干预措施: Cutting Balloon (Device)

结局指标

主要结局

Primary Endpoint

时间窗: 30 days

Post-procedural stent area at the point of maximum calcification as measured by intravascular imaging

次要结局

  • Peri-procedural Myocardial Infarction(within 48 hours of index procedure)
  • Procedural Cost(Index procedure)
  • Strategy success(Index procedure)
  • Procedural success(Index procedure)
  • Angiographic success(Index procedure)
  • In-hospital MACCE(hospitalization)
  • 30 Day MACCE(30 days)

研究者

发起方
Baim Institute for Clinical Research
申办方类型
Other
责任方
Sponsor

研究点 (22)

Loading locations...

相似试验